ArticleDiabetologia2009
C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes.
Article in Diabetologia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Reference Standards for C-Peptide in Korean Population: A Korean Endocrine Hormone Reference Standard Data Center Study.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Copper(II) Affects the Biochemical Behavior of Proinsulin C-peptide by Forming Ternary Complexes with Serum Albumin.Journal of the American Chemical Society · 2023Article
- The role of C-peptide in diabetes and its complications: an updated review.Frontiers in endocrinology · 2023Review
- Insights into the physiology of C-peptide.Physiological research · 2020Review
- Autocrine C-peptide protects INS1 β cells against palmitic acid-induced oxidative stress in peroxisomes by inducing catalase.Endocrinology, diabetes & metabolism · 2020Article
- C-peptide exhibits a late induction effect on matrix metallopeptidase-9 in high glucose-stimulated rat mesangial cells.Experimental and therapeutic medicine · 2016Article
- Physiological effects and therapeutic potential of proinsulin C-peptide.American journal of physiology. Endocrinology and metabolism · 2014Review
- C-Peptide and its career from innocent bystander to active player in diabetic atherogenesis.Current atherosclerosis reports · 2013Review
- Article
- Review
- C-peptide: a new mediator of atherosclerosis in diabetes.Mediators of inflammation · 2012Review
- C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012Article
- Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein.Diabetologia · 2010Article
- Proinsulin C-peptide regulates ribosomal RNA expression.The Journal of biological chemistry · 2010Article
- Breakthrough in diabetes therapy ... Just around the corner?The review of diabetic studies : RDS · 2009Article
- C-Peptide in the vessel wall.The review of diabetic studies : RDS · 2009Article
- Molecular effects of C-Peptide in microvascular blood flow regulation.The review of diabetic studies : RDS · 2009Article
- Anti-inflammatory properties of C-Peptide.The review of diabetic studies : RDS · 2009Article
- The beneficial effects of C-Peptide on diabetic polyneuropathy.The review of diabetic studies : RDS · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
aims/hypothesisThere is increasing evidence that C-peptide exerts intracellular effects in a variety of cells and could be beneficial in patients with type 1 diabetes. Exactly how C-peptide achieves these effects, however, is unknown. Recent reports showed that C-peptide internalised in the cytoplasm of HEK-293 and Swiss 3T3 cells, where it was not degraded for at least 1 h after uptake. In this study, we investigated the hypothesis that C-peptide is internalised via an endocytic pathway and traffics to classic endocytic organelles, such as endosomes and lysosomes.
methodsWe studied the internalisation of C-peptide in vascular endothelial and smooth muscle cells, two relevant targets of C-peptide activity, by using Alexa Fluor-labelled C-peptide probes in living cells and immunohistochemistry employing confocal laser-scanning microscopy. To examine trafficking to subcellular compartments, we used fluorescent constructs tagged to RAB5A, member RAS oncogene family (RAB5A) to identify early endosomes, or to lysosomal-associated membrane protein 1 (LAMP1) to identify lysosomes.
resultsC-peptide internalised in the cytoplasm of cells within punctate structures identified as early endosomes. Internalisation was clearly detectable after 10 min of incubation and was blocked at 4 degrees C as well as with excess of unlabelled C-peptide. A minor fraction of vesicles, which increased with culture time, co-localised with lysosomes. Uptake of C-peptide was reduced by monodansylcadaverine, a pharmacological compound that blocks clathrin-mediated endocytosis, and by nocodazole, which disrupts microtubule assembly. CONCLUSIONS/
interpretationC-peptide internalises in the cytoplasm of cells by endocytosis, as demonstrated by its localisation in early endosomes. Endosomes might represent a signalling station, through which C-peptide might achieve its cellular effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.